Rieg T S, Maestrello A M, Aravich P F
Department of Anatomy and Neurobiology, Eastern Virginia Medical School, Norfolk.
Am J Clin Nutr. 1994 Oct;60(4):494-500. doi: 10.1093/ajcn/60.4.494.
It has been proposed that anorexia nervosa (AN) is treatable with serotonergic (5-HT) agonists. It seems paradoxical to treat a disorder characterized by reduced food intake with appetite suppressants. The effects of the indirect-acting 5-HT agonist D-fenfluramine on activity-based anorexia (ABA) were investigated, coincident with ABA (experiment 1), and after tolerance and weight cycling (experiment 2). Rats were chronically infused with D-fenfluramine by using subcutaneous mini-pumps and then tested for susceptibility to ABA (22.5 h free running wheel access, 1.5 h access to food). Concurrent D-fenfluramine increased the risk of ABA by decreasing food consumption. Conversely, D-fenfluramine reduced the incidence of ABA in tolerant rats with a history of weight cycling. Therefore, the effects of D-fenfluramine depend on whether drug administration coincides with ABA or whether tolerance and weight cycling precede ABA onset. The results were related to the metabolic effects of weight cycling and the treatment of anorexia nervosa.
有人提出，神经性厌食症（AN）可用血清素能（5-HT）激动剂进行治疗。用食欲抑制剂来治疗一种以食物摄入量减少为特征的疾病，这似乎自相矛盾。研究了间接作用的5-HT激动剂右芬氟拉明对基于活动的厌食症（ABA）的影响，分别在ABA发生期间（实验1）以及耐受和体重循环之后（实验2）进行研究。通过皮下微型泵给大鼠长期输注右芬氟拉明，然后测试其对ABA的易感性（自由使用跑轮22.5小时，进食1.5小时）。同时使用右芬氟拉明会通过减少食物消耗增加患ABA的风险。相反，右芬氟拉明降低了有体重循环史的耐受大鼠中ABA的发生率。因此，右芬氟拉明的作用取决于给药是否与ABA同时发生，或者耐受和体重循环是否先于ABA发作。这些结果与体重循环的代谢影响以及神经性厌食症的治疗有关。
